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Abstract: Tobacco smoking is the major cause of disability and death in the United States and around
the world. In addition, tobacco dependence and addiction express themselves as complex behaviors
involving an interplay of genetics, environment, and psychological state. Mouse genetic studies
could potentially elucidate the novel genes and/or gene networks regulating various aspects of
nicotine dependence. Using the closely related C57BL/6 (B6) mice substrains, recent reports have
noted phenotypic differences within C57BL/6J (B6J) and C57BL/6N (B6N) mice for some drugs of
abuse: alcohol, opiates, and cocaine. However, the differences in nicotine’s effects have not yet been
described in these substrains. We examined the phenotypic differences in these substrains following
the acute and repeated administration of nicotine in several pharmacological measures, including
locomotion (after acute and repeated exposure), body temperature, nociception, and anxiety-like
behaviors. We report substrain differences in the pharmacological effects of acute and repeated
nicotine administration in the B6 substrains. Overall, we show enhanced nicotine sensitivity to
locomotion, hypothermia, antinociception, and anxiety-like behaviors in the B6J mouse substrain
compared to B6N. In the repeated administration paradigm, both the B6N and B6J substrains showed
no sensitized locomotor responses after repeated exposure to nicotine at the two doses tested.
This study thus provides evidence that the B6 mouse substrains may be useful for genetic studies to
elucidate some of the genetic variants involved in tobacco dependence and addiction.
Keywords: nicotine; acute effects; mice; C57BL/6 substrains
1. Introduction
The World Health Organization (WHO) reports more than seven million deaths each year from
direct tobacco use, which is estimated to rise to 10 million deaths per year by the year 2030 [1–3]. Tobacco
smoking, however, is the major cause of disability and death in the United States and around the
world [2]. Many smokers still face immense difficulty quitting and remaining tobacco-free permanently
despite numerous informational efforts on the hazards of tobacco smoking and other control efforts [4–6].
Tobacco dependence expresses as a complex interplay of several behaviors, likely involving an even
more complex play of several genes, each making a small contribution. Twin studies reported a
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tobacco dependence heritability estimate of 50–70% [7,8]. Over the years, several nicotinic receptor
gene variants have been implicated in nicotine dependence (CHRNA5-CHRNA3-CHRNB4 within the
q25.1 region of chromosome 15, as well as in the primary metabolism gene, CYP2A6). However,
these genetic variants explain only a small proportion of the genetic risk of tobacco-use initiation and
dependence [9–11]. The successful identification of replicable “nicotine addiction genes” has eluded
the scientific community for many decades, owing to the lack of consistent definitions of phenotypes
across various cohorts, as well as a deficit in statistical power [12]. A discovery-based approach to
genetic mapping known as “Quantitative trait locus (QTL) mapping” has been successfully used in the
identification of genetic variants underlying several complex phenotypes [13,14]. This approach allows
the mapping of regions of polymorphism within the genome to narrow intervals, thus facilitating the
identification of causative variants associated with complex behaviors. However, while preclinical
QTL mapping models of dependence and addiction-like behaviors have been described in numerous
rodent studies with alcohol and other drugs of abuse, very few reports exist for nicotine. Significant
QTLs in mice using F2 crosses were identified for oral nicotine intake in the preference test [15] and in
the effect of systemic nicotine on locomotor activity [16,17]. However, no confirmation or fine-mapping
for potential candidate genes were reported in these studies, which is probably due to the high genetic
complexity underlying a QTL, combined with large linkage disequilibrium blocks which can hinder
gene identification [14].
Reduced complexity crosses (RCC) offer a solution and have been successfully used to identify
quantitative trait nucleotides (QTN). Compared to the inbred reference strain, C57BL/6J (BJ), most
classical inbred strains contain approximately 5 million variants; the C57BL/6NJ (B6N) substrain, a
closely related inbred substrain, contains roughly 30,000 variants in comparison [18,19]. Thus, between
both substrains, the identification of causal genes and variants using QTL mapping is greatly facilitated
due to the stark reduction in genetic complexity [20–23]. In our previous report, we mapped the genetic
basis of variation in cocaine’s effects on locomotor activation and sensitization within parental strains
using the C57BL/6 (B6) substrains [22]. We report substrain differences in B6N versus B6J mice, where
the B6N substrain demonstrated a lower response to both cocaine and methamphetamine in an acute
and sensitized model compared to B6J mice. Using QTL mapping, we identified a causative variant on
QTL mid-chromosome 11 that produced a nonsynonymous mutation (S968F) in the cytoplasmic FMRP
interacting protein 2 (Cyfip2). These results provided support for Cyfip2 as a causal agent underlying
cocaine’s effects on locomotor activity and sensitivity. This same variant was identified in another
QTL mapping study for binge eating behavior [23]. Thus, Cyfip2 seems to regulate both natural and
drug-induced behaviors.
The emergence of tobacco dependence is primarily due to the psychoactive properties of nicotine.
Nicotine has broad pharmacological effects on humans and animals [24]. Under first exposure to
nicotine, either by inhalation or through other routes of administration, subjects report relaxation,
alertness, dizziness, and nausea, amongst other effects [25]. These initial responses may play significant
roles in sustained smoking and the subsequent development of dependence to nicotine. However, in
most human genetic studies, these initial effects are rarely included in association testing. Importantly,
early animal behavioral studies established that various inbred mice strains were differentially sensitive
to the initial effects of nicotine. These genetic analyses showed that nicotine’s pharmacological effects
on locomotion, body temperature, nociception, and seizures are heritable [26,27]. It is unknown
whether nicotine’s differential pharmacological sensitivity extends to the B6 substrains. This is
important to investigate before eQTLs can be performed. We, therefore, evaluated possible differences
in nicotine pharmacological responses and pharmacokinetics after acute and repeated administration.
Differences in nicotine’s initial responses between the B6N and B6J mouse substrains in several
pharmacological measures were evaluated: locomotion (after acute and repeated exposure), body
temperature, nociception, and anxiety-like behaviors.
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2. Materials and Methods
2.1. Mice
Adult male C57BL/6J (B6J) (The Jackson Laboratory; JAX—Bar Harbor, ME, USA), and C57BL/
6NCrl mice (B6N) (Charles River Laboratories—Wilmington, MA, USA) aged 8–10 weeks at the
beginning of the experiments were used throughout the study. Mice were acclimated to the vivarium
for a week and handled prior to any behavioral testing. Separate cohorts of mice were used for the
studies, except for their body temperatures and acute locomotor activity to avoid repetitive testing; and
because nicotine has different potencies in various behavioral tests. Mice were housed in accordance to
the Association for Assessment and Accreditation of Laboratory Animal Care at 21 ◦C in an approved
animal care facility at Virginia Commonwealth University with humidity-control. Each cage was
housed with groups of four mice who had free access to standard rodent chow (#7012, Envigo Teklad,
Madison, WI, USA) and water throughout the study. Teklad corn cob bedding (#7097, Envigo Teklad,
Madison, WI, USA) was used in the mouse cages and was changed weekly. A 12 h light/dark cycle
paradigm was used, and all tests were performed within the light cycle from 7:00 to 19:00. All studies
were authorized by the Institutional Animal Care and Use Committee at Virginia Commonwealth
University and implemented according to the National Institutes of Health’s Guide for the Care and
Use of Laboratory Animals.
2.2. Drugs
(-)-Nicotine hydrogen tartrate [(-)-1-methyl-2-(3- pyridyl) pyrrolidine (þ)-bitartrate] was procured
from Sigma-Aldrich Inc. (St. Louis, MO, USA). Solutions were made by dissolving nicotine in
physiologic saline consisting of 0.9% sodium chloride. The route of administration was through
subcutaneous (s.c.) injection. Each animal received a total volume of 1 mL per 100 g (Volume/Body
Weight) unless stated otherwise. Every dose is represented as the free base of the drug.
2.3. Behavioral Tests
2.3.1. Tail-Flick Test
To test antinociception in mice, the tail-flick assay was used according to D’Amour and Smith
(1941), as adapted by Dewey et al. (1970) [28,29]. Baseline measurements were obtained for all mice
before treatment. Then, test-latencies were measured 5 mins after administration of either vehicle or
nicotine (s.c.). To prevent damage of mouse tissue, a cut-off time latency of 10 s was set. To calculate
antinociceptive response, data were computed as the percent maximum possible effect (% MPE),
calculated as [(test-control)/(10-control)] × 100%.
2.3.2. Hot Plate Test
The hot plate test is another test of antinociception and was performed according to the protocols
reported by Eddy and Leimbach (1953), along with Atwell and Jacobson (1978) [30,31]. Baseline
measurements were obtained for all mice before treatment. Then, test-latencies were measured
5 min after the administration of either the vehicle or nicotine (s.c.). Mice were observed to jump
or lick their paws as a positive response. Test latencies were determined by placing mice unto a
10 cm wide glass cylinder on a hot plate (Thermojust Apparatus, Columbus, OH, USA), adjusted
to 55.0 ◦C. A cut-off time latency of 40 s was set to prevent damage of mouse tissue. To calculate
antinociceptive response, data were computed as the percent maximum possible effect (% MPE),
calculated as [(test-control)/(40-control)] × 100%.
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2.3.3. Locomotor Activity
Acute Nicotine
To test for locomotion, mice were individually stationed into photocell activity cages (Omnitech
Electronics, Columbus, OH, USA) measuring 28 × 16.5 cm. Photocell beam interruptions (two banks of
eight cells each) were recorded for 30 min following a 5 min pretreatment of either vehicle or nicotine
(0.5 or 1 mg/kg) s.c.
Repeated Administration
Initially, mice injections started with subcutaneous administration of saline for three days, followed
by administration of nicotine at 0.5 or 1.0 mg/kg for five days. Then, after a 2-day washout period
(day 6 to day 8), mice were challenged with the same dose of nicotine. Mice were tested daily for
locomotion (a similar procedure using locomotor activity boxes was followed as described above in
the acute nicotine experiment) for five minutes following subcutaneous administration of either saline
(days 1–3) or nicotine (days 4–8 and 12).
2.3.4. Body Temperature
Body temperatures were measured rectally using a thermistor probe (inserted 24 mm) and digital
thermometer (Yellow Springs Instrument Co., Yellow Springs, OH, USA). Baseline measurements were
obtained prior to saline or nicotine injection and after 30 min of the injection of the same treatments.
Data were calculated as the difference in rectal temperature before and after treatment. The variation
of ambient temperature in the laboratory ranged from 21 ◦C to 24 ◦C.
2.3.5. Elevated Plus-Maze
An elevated plus maze (EPM) was used to assess anxiety-like behaviors for this study. The EPM
is made of gray plexiglass mounted on a base that is raised a total length of 60 cm from the ground.
It has two open arms (23 × 6.0 cm) and two enclosed arms (23 × 6 × 15 cm), which extend from a
central platform. The apparatus is illuminated by a single source of fluorescent lights (350 lux intensity)
hung from the ceiling of the room. Mice were tested for 5 min following subcutaneous injection
of either saline or nicotine where they are put in the center of the maze and permitted to willingly
explore. The total amount of time spent within the open arms of the EPM, and the total number of
crossings between the arms with the 5 min were scored automatically using a photocell beams system.
After each test, the equipment was thoroughly wiped.
2.4. Nicotine and Cotinine Plasma Levels
Blood samples from adult male B6J and B6N mice were collected at 5, 15, 30, 60, and 90 min after
subcutaneous injection of 1 mg/kg nicotine. CO2 was used in the anesthetization of the mice, and right
before death, blood samples were collected via intra-cardiac puncture. The collected blood samples
were preserved in sodium heparin blood collection tubes and subsequently centrifuged at 1400× g
for ten min. The resulting serum was collected and then stored at −4 ◦C. HPLC/MS/MS analysis was
used to quantify the serum levels of nicotine and cotinine in blood samples. Separate groups of mice
were used.
2.4.1. HPLC/MS/MS Analysis of Nicotine and Cotinine
Specimen Extraction
The methods for the specimen extractions were performed according to AlSharari et al., 2013 [32].
A 50 µL solution of internal standard containing 50 ng of cotinine-d3 and nicotine-d4 in methanol was
added to 200 µL of aliquoted serum extracted from specimens. Next, 100 µL of ammonium hydroxide
(5M), followed by 2 mL methylene chloride, was added to the mixture. The solution was vortexed
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and subsequently centrifuged at 3000 rpm for 5 min at 4 ◦C. The organic layer was extracted, and the
aqueous phase was washed twice using 2 mL of methylene chloride. The resulting organic layers were
then combined in a new test tube with 500 µL of HCL (25 mM) in methanol and dried using nitrogen.
The samples were placed in HPLC/MS/MS auto-sampler vials for analysis after reconstituting with
100 µL of the mobile phase.
Instrumental Analysis
Instrumental analyses were performed using an Applied Biosystems (3200 Qtrap) and Shimadzu
SCL HPLC system controlled by Analyst 1.4.2 software with turbo V source for TurbolonSpray. A 3 mm
by 50 mm, 5 micron Hypersil Gold system (Thermo Scientific, Waltham, MA, USA) was used for
chromatographic separation. The mobile phase, maintained at a flow rate of 0.5 mL/min, consisted of
10 mM ammonium folate and methanol at a ratio of 10:90 (V/V). A positive multiple reaction monitoring
(MRM) acquisition mode was utilized; with monitored ion transitions as follows: nicotine (163 > 130;
163 > 117), nicotine-d4 (167 > 134), cotinine (177 > 80; 177 > 98), and cotinine-d3 (180 > 80). Time set for
each chromatographic separation was 2 min. Based on a linear regression generated from peak area
ratios of each drug to its deuterated internal standard, a calibration curve (12.5 ng/mL –500 ng/mL)
was designed for each compound. The internal standard for 3-hydroxycotinine was Cotinine-d3.
2.4.2. Pharmacokinetic Analysis
A Phoenix WINNONLIN 6.4 program (Certara, Princeton, NJ, USA) was used for all
pharmacokinetic calculations. Statistical comparisons of the pharmacokinetic parameters were
performed using two-tailed t-tests. Terminal half-live values of nicotine and cotinine were obtained
through extrapolation of regression analyses calculated from terminal sampling points. Each regression
analysis used data from no less than three different time-points in the terminal phase, and visual
inspection of each analysis was congruent with a straight line on a log-transformed scale. The trapezoidal
rule was used to determine AUC0-60, AUC0-90 and AUC0-inf values.
2.5. Statistical Analysis
Behavioral data were analyzed using GraphPad Prism software, version 8.1.2 (GraphPad Software,
Inc., La Jolla, CA, USA) and expressed as the mean ± S.E.M. Statistical analyses were conducted using
a two-way analysis of variance test (ANOVA), followed by a Holm-Sidak post hoc test, unless specified
otherwise. ED50 values with 95% confidence limits (CL) were also calculated for the acute studies by
unweighted least-squares linear regression as described by Tallarida and Murray (1987) [33]. If the
confidence limit values did not overlap, the shift in the dose-response curve was considered significant.
Differences were considered significant at p < 0.05.
3. Results
3.1. Effects of Acute Nicotine on Thermal Antinociception, Locomotion, and Body Temperature
We investigated the effects of acute nicotine administration on thermal antinociception, locomotor
activity, and body temperature. Nicotine produced a dose-responsive increase in the tail-flick latency
(Figure 1A) in the B6J and B6N substrains with an ED50 (±CL) of 1.3 (0.56–1.89) and 5.9 (3.1–11.23) mg/kg,
respectively (Table 1).
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Figure 1. Effects of acute nicotine on th rmal antinociception, locom tor activity, and body temperature
in the B6J and B6N substrains. Thermal ntinociception is expressed as the ercentage of th maximal
possible effect in (a) tail fli k and (b) hot pl te test. (c) Locomo ion resp nse t acute ico ine in
male B6J a d B6N mice. (d) Body temperature in response to acute nicotine in male B6J and B6N
mice. Nicotine (0.1, 0.5, 1, and 2 mg/kg) or the vehicle (0.9% saline) was administered subcutaneously.
Each data p int for thermal ant ociception is represent d by the mean %MPE + SEM. Significant
difference is based on Holm-Sidak post-h c test following the w -way ANOVA betw en both substrains
(* p < 0.05, *** p < 0.001, **** p < . 001), n = 8/group.
Table 1. A summary of nicotine’s potency in the tail-flick, hot plate, body temperature and locomotor
activity tests after acute administration in male B6J and B6N mice. Potency is expressed as the ED50 ±
confidence limits (mg/kg). Each group contained 8 mice. * CL of ED50 values do not overlap.
Test B6J (mg/kg) B6N (mg/kg)
Tail flick 1.3 (0.56–1.89) 5.9 (3.1–11.23) *
Hot plate 1.08 (0.83–1.38) 7.79 (3.56–13.41) *
Body temperature 0.57 (0.37–0.88) 1.15 (0.96–2.13) *
A two-way ANOVA revealed significant effects of dose, strain, and interaction in the tail-flick test
(Fstrain (1, 56) = 18.73, p < 0.0001; Fdose (3, 56) = 26.95, p < 0.0001; Fstrain×dose (3, 56) = 4.061, p = 0.0111;
Figure 1A), and hot plate test (Fstrain (1, 56) = 19.57, p < 0.0001; Fdose (3, 56) = 13.10, p < 0.0001;
Fstrain×dose (3, 56) = 53.84, p < 0.0001; Figure 1B). Similarly, the B6J substrain demonstrated an increased
nicotine potency in the hot plate test in a dose-dependent manner (as shown in Figure 1B), compared
to the B6N substrain with an ED50 (±CL) of 1.08 (0.83–1.38) and 7.79 (3.56–13.41) mg/kg, respectively
(Table 1). While nicotine produced a dose-responsive decrease in locomotor activity in B6J mice
(Figure 1C), the decrease was only significant at the dose of 1 mg/kg in the B6N substrain. The two-way
ANOVA analysis revealed a significant interaction between the strain and dose on locomotor activity
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(Fstrain×dose (3, 56) = 6.822, p = 0.0005; Figure 1C), as well as a dose-related effect of nicotine treatment
(Fdose (3, 56) = 20.44, p < 0.0001; Figure 1C). Although there was no main effect of the strain in the
analysis, a Holm–Sidak post hoc comparison test revealed differences in the B6J and B6N strains
at the highest dose of nicotine (1.0 mg/kg) we tested. Finally, nicotine-induced hypothermia was
dose-dependent in both the B6J and B6N substrains (Figure 1D) with an ED50 (±CL) of 0.57 (0.37–0.88)
and 1.15 (0.96–2.13) mg/kg, respectively (Table 1). The two-way ANOVA revealed significant effects of
the dose, strain, and interaction within the body temperature changes (Fstrain (1, 56) = 38.83, p < 0.0001;
Fdose (3, 56) = 83.50, p < 0.0001; Fstrain×dose (3, 56) = 9.987, p < 0.0001; Figure 1D).
3.2. Dichotomous Effect of Nicotine on Anxiety-Like Behavior in the EPM Assay
The EPM assay is a well validated anxiolytic drug efficacy test with great predictive validity [34,35].
Similar to a previous report, we demonstrated that nicotine has a dichotomous effect on anxiety-like
behavior in the EPM assay [34]. In the B6J strain, we found that mice receiving a lower dose of nicotine
(0.05 mg/kg) spent more time in the open arms of the EPM than the mice receiving higher doses
(0.1 and 0.25 mg/kg), which is indicative of anxiolytic-like behavior (Figure 2A). This response was
observed to have a greater effect on the B6J mice administered the lowest dose of nicotine (0.05 mg/kg),
who spent more time in the open arms of the EPM compared to the B6N mice at all administered
doses. In contrast, B6N mice showed no preference for the open arms of the EPM at 0.05 or 0.1 mg/kg.
Only at the highest dose (0.25 mg/kg) did they show a significant increase in the time spent in the open
arm of the EPM. Interestingly, the response for B6J mice was dissipated at this dose, and the B6N mice
spent more time in the open arms of the EPM than the B6J mice. The two-way ANOVA of the EPM
test revealed significant effects of the dose, strain, and interaction (Fstrain (1, 56) = 28.27 p < 0.0001;
Fdose (3, 56) = 29.51 p < 0.0001; Fstrain×dose = (3, 56) = 65.27, p < 0.0001; Figure 2A). We report no effect
of nicotine on the total numbers of crosses between arms, thereby suggesting the non-specific effects of
nicotine on locomotion (Figure 2B).
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Figure 2. The effects of acute nicotine on anxiety-like behaviors in B6J and B6N substrains. In the B6J
strain, mice receiving a lower dose of nicotine (0.05 mg/kg) spent more time in the open arms of the
elevated plus maze than mice receiving higher doses (0.1 and 0.25 mg/kg), indicative of anxiolytic-like
behavior. In stark contrast, B6N mice show no preference for the open arms of the EPM at 0.05 or
0.1 mg/kg. Only at the highest dose (0.25 mg/kg) do they show a significant increase in the time spent in
the open arm of the EPM. There was no effect of nicotine on the total numbers of crosses between arms
to suggest non-specific effects of nicotine on locomotion. The data are reported as mean + SE. Each data
point is representative of the averaged mouse response at the given dose. Significant difference is based
on Holm-Sidak post hoc test following two-way ANOVA between both substrains (**** p < 0.0001),
n = 8/group.
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3.3. Impact of Repeated Drug Administration on Locomotor Activity
At a low dose of nicotine (0.5 mg/kg), differences between the B6J and B6N substrains were
observed (Figure 3A). A multiple t-test analysis with Holm–Sidak correction for multiple comparisons
shows significant differences between substrains for low-dose nicotine on day 1 (day 1 of saline
administration; p = 0.02), day 4 (day 1 of nicotine administration; p = 0.03), and day 12 (nicotine
challenge; p = 0.0016). However, mice treated with the first dose of nicotine (day 4) were significantly
different from the mice that were challenged with nicotine at day 12 for both strains. When compared
to day 1, only B6J mice were significantly different from those challenged with nicotine on day 12
(Figure 3B). At the higher dose of nicotine (1 mg/kg), the multiple t-test analysis with Holm–Sidak
correction for multiple comparisons did not yield any significant difference between substrains on any
of the days (Figure 3C). Further, when compared to day 1, both the B6J and B6N mice were significantly
lower from the respective challenge with nicotine on day 12 (Figure 3D).
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Figure 3. Locomotor sensitization to repeated nicotine administration in male B6J and B6N substrains.
Mice were injected s.c. with 0.9% saline for 3 days, nicotine (0.5 or 1.0 mg/kg) for 5 days, and after
a washout period (day 6 to day 8), mice were challenged with the same dose of nicotine. Each day,
five minutes post subcutaneous administration of the vehicle (0.9% saline) or nicotine, their locomotor
activity was measured for 30 min. (A,B) Locomotor response to 0.5 mg/kg nicotine, and (C,D) locomotor
response to 1.0 mg/kg nicotine. Each data point is representative of the averaged mouse response at the
given time-point 30 min post injection. The data are expressed as the number of photocell interruptions
and reported as the mean ± SE of 12–15 mice. * p < 0.05, ** p < 0.01 from Holm-Sidak post hoc test
following a multiple t-test analysis between both substrains at various time points, or #### p < 0.0001
from the Holm–Sidak post hoc test following a two-way RM repeated measure ANOVA, comparing
the averaged mouse response at day 1 and day 12 (challenge day).
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3.4. Nicotine Metabolism and Kinetics Do not Differ between the B6N and B6J Substrains after Acute
Administration of Nicotine
Next, we determined if this effect would be replicated in both substrains demonstrated by
differences in the kinetics of nicotine after acute administration. The time course of nicotine and its
main metabolite, cotinine, were determined. We observed no significant differences between both
strains in the area under the curve (AUC), Cmax, or half-life of the metabolism of nicotine (Figure 4A and
Table 2). Interestingly, the pharmacokinetic parameters after acute administration of 1 mg/kg nicotine
(s.c.) yielded significant differences in the B6J and B6N mice for the AUC measurements of serum
cotinine concentrations. Thus, while both strains showed similar elimination half-lives for nicotine,
the overall AUC0-90 value of cotinine was significantly higher in the B6J strain (7000 ± 418 min ng/mL)
than in the B6N strain (5740 ± 384 min ng/mL), p = 0.05 (Figure 4B and Table 2) suggesting differences
in cotinine metabolism. The two-way repeated measure RM ANOVA with a Holm–Sidak post hoc
test of the nicotine time-course yielded no significant effect of the interaction between time and strain
(Fstrain×time (4,40) = 0.2491, p = 0.9085, Figure 4A). It also showed no significant effect for the interaction
between time and substrains in the cotinine time-course (Fstrain×dose (4,40) = 0.5813, p = 0.06779,
Figure 4B).
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Table 2. Summary of pharmacokinetic parameters after acute nicotine administration (1 mg/kg,
s.c.) in male B6J and B6N mice. Statistical comparisons were performed using two-tailed t-test.
N.S = Not significant.
Nicotine Cotinine
Mean
(SE)
AUC0-90
(min ng/mL)
AUC0-inf
(min ng/mL)
Cmax
(ng/mL)
T1/2
(min)
AUC0-90
(min ng/mL)
AUC0-inf
(min ng/mL)
Cmax
(ng/mL)
6N 4610(126)
5200
(136)
216
(20.6)
17.2
(1.43)
5740
(384)
7230
(713)
129
(12.9)
6J 4930(380)
5880
(741)
206
(30)
20.5
3.68
7000
(418)
8780
(506)
131
(7.16)
Comparison N.S. N.S. N.S. N.S. P = 0.05 N.S. N.S.
3.5. B6N and B6J Substrains Differ at Basal Levels
Baseline responses in B6N and B6J mice in the tail-flick, hot plate, locomotion test, and body
temperature from the previous experiments were analyzed. Figure 5 demonstrates that the B6N and
B6J substrains differ at basal levels. Significant differences were observed in the tail-flick (t = 3.563,
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df = 44, p = 0.0009), hot plate (t = 4.324, df = 44, p < 0.0001), and locomotor activity (t = 2.680, df = 34,
p = 0.0113) tests based on an unpaired two-sided t-test as seen in Figure 5A–C, respectively. Although
the B6N mice displayed higher locomotion and nociceptive latencies in the tail flick and hot plate assay
(indicative of enhanced nociceptive thresholds compared to the B6J mice), no significant differences
were observed in the body temperatures between both substrains (t = 1.261, df = 52, p = 0.2130),
as shown in Figure 5D.Brain Sci. 2019, 9, x FOR PEER REVIEW 10 of 15 
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Figure 5. Basal responses for the B6J and B6N substrains. Basal thermal nociception in the male B6J
versus B6N substrains demonstrated by latency (sec) in (A) the tail flick and (B) the hot plate tests
(n 23/substrain). (C) The basal locomotion response in male B6J and B6N mice (n = 18/substrain).
(D) The b sal body temperature in male B6J and B6N mouse strains (n = 27/substrain). All data
are hown as the mean ± SE. Each data oint is repres ntative of each individual mouse response.
Significa t diff rences between substrains are based on an unpaired t-test (* p < 0.05, *** p < .001,
**** p < 0.0001).
4. Discussion
The primary goal of this paper was to evaluate the differences between the C57BL/6N (B6N) and
C57BL/6J (B6J) mouse substrains in response to cute and chronic nicotine. We report, for the first time,
substrai differences in the pharmacological effects of acute nd repeated nicotine admini tration in
these ubs rains. We expanded the catalog of behavioral differences in the sensitivity between the
B6J and B6N substrains in several pharmacological measures: locomotion ( fter acute and repeated
exposure), body t mperature, ocicepti n, and anxiet -like behaviors. Overall, we identified enhanced
nicotine sensitivity to antinociception, hypothermia, locomotion, and anxiety-like behaviors in the
B6J versus B6N substrains after acute dosing (Figure 1). Here, we find that nicotine produced a
dose-dependent increase in latency in the tail-flick and hot plate tests in both the B6J and B6N substrains
(Figure 1A,B). However, the B6J substrain demonstrates a more pronounced thermal antinociceptive
response in both the tail-flick and hot plate test, as well as an increased potency to nicotine in both tests
compared to B6J mice (Table 1). In addition, nicotine dose-dependently induced hypothermia in both
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the B6J and B6N substrains (Figure 1D). Again, the B6J substrain demonstrated a more pronounced
response to nicotine-induced hypothermia with an increased potency to nicotine compared to the B6N
strain (Table 1).
Locomotor activity has long been widely used to study the effects of nicotine in rodents [22,36–38].
Nicotine produced a reduction in locomotion in a dose-related manner in both substrains. This effect is
more pronounced in the B6J substrain, demonstrating an increased sensitivity to nicotine compared
to the B6N mice (Figure 1C). We then explored the difference in locomotor sensitization between
the two substrains after repeated administration of nicotine. Literature has demonstrated that upon
repeated administration of psychostimulants, animals display a progressively greater behavioral
response, regulated by “experience-dependent neuronal plasticity”, which is thought to be a key event
in addiction [22,39]. However, our results did not show a sensitized locomotor response in either of the
substrains after repeated exposure to nicotine at the two doses tested (0.5 and 1 mg/kg). Nevertheless,
tolerance to the locomotor depressant effect of a challenge dose of nicotine on day 12 was observed after
repeated injection of nicotine at 0.5 mg/kg in the B6N mice only (Figure 3). At the higher dose of nicotine
(1 mg/kg), both substrains did not display any significant sensitization after repeated administration
of the drug. In contrast to nicotine, the B6J mice showed a larger sensitized locomotor response to
cocaine than the B6N mice, as reported by Kumar et al., 2013 [22]. This difference of sensitivity in
locomotor activity within the closely related B6N and B6J substrains has helped identify a nucleotide
level mutation that regulates the cocaine response within the Cyfip2 using QTL analysis. In the EPM
assay, we demonstrated that nicotine produces a dichotomous effect on anxiety-like behaviors. In B6J
mice, only the lower doses of nicotine (0.05 mg/kg) increased the time spent in the open arms of
the EPM compared to the vehicle group, which is indicative of anxiolytic-like behavior (Figure 2A).
This effect dissipated at higher doses (0.1 and 0.25 mg/kg). In contrast, an increase in the time spent in
the open arms was only seen at the highest dose of nicotine (0.25 mg/kg) in the B6N mice. Overall, our
findings are consistent with previously published mouse studies that show that low doses of nicotine
promote anxiolytic-like behavior, while higher doses promote anxiogenic-like behaviors [34,40]. This is
clinically relevant to human smokers because studies reveal that many smokers report tobacco-use as a
way to relieve anxiety. Importantly, the effect of nicotine on anxiety in humans appears to multifactorial,
including a genetic predisposition for anxiety. Lasser et al. report that individuals with a diagnosis of
anxiety disorders are twice as likely to smoke than other persons [41].
Next, we explored if pharmacokinetic differences within the substrains could explain the observable
phenotypic differences by measuring the time course of nicotine (Figure 4A) and its main active
metabolite, cotinine (Figure 4B). We found that these differences are not due to differences in nicotine
pharmacokinetics (Table 1). The AUC, Cmax, and elimination half-life of nicotine were similar in both
substrains and consistent with published studies on nicotine pharmacokinetics in C57BL/6J mice [42].
However, while both strains showed a similar elimination of half-live for nicotine, the cotinine
levels were significantly higher in B6J mice (Table 2). While it is possible that differences in cotinine
pharmacokinetics could have potentially contributed to the observed substrain pharmacological
differences, we believe that this contribution is minimal, since cotinine is reported to be inactive
after systemic administration in mice in the pharmacological responses measured in our studies [43].
Interestingly, C57BL/6J mice have been shown to possess a higher clearance rate of cotinine compared
to DBA/2J mice in vivo, despite having similar nicotine clearance [42]. Finally, differences in basal
levels of nociceptive responses in the tail-flick and hot-plate tests, as well as differences in locomotor
activity counts were found between the B6J and B6N mice. The B6N substrain baseline nociceptive
latencies were significantly higher than those of the B6J mice in both tests. However, their baseline
locomotor counts were significantly lower than those of the B6J mice. These findings are similar to
those previously reported in these two substrains [20,22,44]. In addition, no significant differences
were found in the basal body temperature between the two substrains.
The heritable differences in the basal and nicotine response differences described here lend
themselves to genetic mapping using a RCC strategy. Such a strategy has been successful in QTLs for
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behavior, immunity, and physiological phenotypes [20–22,45,46]. This approach has most widely been
utilized in C57BL/6 substrains and has recently been used in non-obese diabetic (NOD) substrains [47].
Presumably, with only 34 SNPs, 2 Indels, and 15 structural variants that lead to coding changes,
causative changes can be quickly identified. It is highly likely that many of these phenotypic changes
are due to eQTLs that are caused by variants in enhancers and promoters. There are an estimated
10,794 total variants between B6J and B6N, or roughly one variant every 260 kb. Given a typical
QTL interval of 20 Mb from a F2 cross, there are expected to be 77 variants between B6N and B6J.
The causal variant can be further filtered with gene expression differences in the tissue of interest.
The similar size interval between a DBA/2J and B6J cross would contain 31914 variants [18]. Thus, the
task of identifying causal variants is highly simplified in the RCC by several orders of magnitude.
We also predict that any variant would have pleiotropic effects. A single variant may be responsible
for many for of the observed basal and nicotine induced changes. A mapping QTL analysis for the
basal and nicotine-induced phenotypes will allow us to better determine the relationship between
these phenotypes. For example, we expect genes that modify nicotine responses to potentially modify
the basal locomotor changes that we observed.
5. Conclusions
In conclusion, our present findings suggest that B6 mouse substrains may be useful for genetic
studies to elucidate some of the genetic differences involved in nicotinic behaviors. This is important to
note because one’s initial sensitivity to a drug plays a critical role in their vulnerability to dependence
and addiction [48]. Since most cigarette smokers do so to relieve the stress, anxiety, and withdrawal
symptoms that come with nicotine dependence, the anxiolytic-like effects of nicotine are also essential
to study. A limitation of our study is the use of only male animals. We acknowledge that it would be
interesting to see if these same substrain differences exist within female cohorts. Another potential
limitation is the use of vendor purchased mice rather than in-house bred mice, which could have
contributed to the observed behavioral differences. However, a previously published study found
that mice bred in-house versus mice purchased from a vendor did not show significant alterations in
their behavior in several measures, including anxiety-like testing and locomotor activity, provided that
the mice were sufficiently acclimated upon arrival [49]. In our hands, mice were acclimated to the
vivarium for a week and handled before any behavioral experimentation. In addition, another study
reported that vendor breeding versus in-house breeding did not alter the B6 substrain differences in
alcohol preference and consumption [50]. While the risk of random epigenetic changes occurring from
vendor breeding is probable, the studies mentioned above support the hypothesis that B6 substrain
differences are most likely due to genetic differences rather than environmental differences. Future
studies will aim to test whether the Cyfip2 (S968F) variant that is known to regulate psychostimulant
response could also contribute to the differences seen in nicotine response.
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